NCT00238368View on ClinicalTrials.gov

Fludeoxyglucose F 18 Positron Emission Tomography in Predicting Risk of Relapse in Patients With Non-Hodgkin's Lymphoma Who Are Undergoing Combination Chemotherapy With or Without Autologous Stem Cell or Bone Marrow Transplant

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 29, 2004

Primary Completion Date

September 17, 2007

Study Completion Date

September 17, 2007

Conditions

Lymphoma

Interventions

BIOLOGICAL

filgrastim

BIOLOGICAL

rituximab

DRUG

busulfan

DRUG

cisplatin

DRUG

cyclophosphamide

DRUG

cytarabine

DRUG

doxorubicin hydrochloride

DRUG

etoposide

DRUG

methylprednisolone

DRUG

prednisone

DRUG

vincristine sulfate

PROCEDURE

autologous bone marrow transplantation

PROCEDURE

peripheral blood stem cell transplantation

PROCEDURE

positron emission tomography

RADIATION

fludeoxyglucose F 18

RADIATION

radiation therapy

Trial Locations (1)

21231-2410

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT00238368 - Fludeoxyglucose F 18 Positron Emission Tomography in Predicting Risk of Relapse in Patients With Non-Hodgkin's Lymphoma Who Are Undergoing Combination Chemotherapy With or Without Autologous Stem Cell or Bone Marrow Transplant | Biotech Hunter | Biotech Hunter